CY1107801T1 - Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης - Google Patents

Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης

Info

Publication number
CY1107801T1
CY1107801T1 CY20071101470T CY071101470T CY1107801T1 CY 1107801 T1 CY1107801 T1 CY 1107801T1 CY 20071101470 T CY20071101470 T CY 20071101470T CY 071101470 T CY071101470 T CY 071101470T CY 1107801 T1 CY1107801 T1 CY 1107801T1
Authority
CY
Cyprus
Prior art keywords
human
polymorphisms
oatp
effect
statinis
Prior art date
Application number
CY20071101470T
Other languages
Greek (el)
English (en)
Inventor
Helen Jean Ambrose
Ruth March
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1107801T1 publication Critical patent/CY1107801T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Semiconductor Lasers (AREA)
CY20071101470T 2003-07-26 2007-11-14 Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης CY1107801T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method
EP04743565A EP1651774B1 (en) 2003-07-26 2004-07-26 Use of polymorphisms in human oatp-c associated with an effect on statin pharmacokinetics in humans in statin therapy

Publications (1)

Publication Number Publication Date
CY1107801T1 true CY1107801T1 (el) 2013-06-19

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101470T CY1107801T1 (el) 2003-07-26 2007-11-14 Χρηση πολυμορφισμων στον ανθρωπινο oatp-c που σχετιζονται με μια επιδραση στη φαρμακοκινητικη στατινης σε ανθρωπους σε θεραπεια στατινης

Country Status (12)

Country Link
US (1) US7700277B2 (cg-RX-API-DMAC7.html)
EP (1) EP1651774B1 (cg-RX-API-DMAC7.html)
JP (1) JP4166257B2 (cg-RX-API-DMAC7.html)
AT (1) ATE373730T1 (cg-RX-API-DMAC7.html)
CY (1) CY1107801T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004009083T2 (cg-RX-API-DMAC7.html)
DK (1) DK1651774T3 (cg-RX-API-DMAC7.html)
ES (1) ES2291899T3 (cg-RX-API-DMAC7.html)
GB (1) GB0317592D0 (cg-RX-API-DMAC7.html)
PL (1) PL1651774T3 (cg-RX-API-DMAC7.html)
PT (1) PT1651774E (cg-RX-API-DMAC7.html)
WO (1) WO2005012566A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008656A2 (en) * 2004-07-21 2006-01-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
WO2009106838A1 (en) * 2008-02-29 2009-09-03 Isis Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
CA2851838A1 (en) 2011-10-13 2013-04-18 Boston Heart Diagnostics Corporation Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) * 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0728218B1 (en) 1993-11-12 2008-01-02 PHRI Properties, Inc. Hybridization probes for nucleic acid detection, universal stems, methods and kits
WO2000008157A2 (en) 1998-08-07 2000-02-17 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) * 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
DE602004009083D1 (de) 2007-10-31
WO2005012566A2 (en) 2005-02-10
WO2005012566A3 (en) 2005-06-16
JP4166257B2 (ja) 2008-10-15
ATE373730T1 (de) 2007-10-15
JP2007500005A (ja) 2007-01-11
DK1651774T3 (da) 2008-01-07
DE602004009083T2 (de) 2008-06-19
US20070031838A1 (en) 2007-02-08
PL1651774T3 (pl) 2007-12-31
EP1651774B1 (en) 2007-09-19
US7700277B2 (en) 2010-04-20
EP1651774A2 (en) 2006-05-03
PT1651774E (pt) 2007-11-16
GB0317592D0 (en) 2003-08-27
ES2291899T3 (es) 2008-03-01

Similar Documents

Publication Publication Date Title
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
ATE428411T1 (de) Hdl-verstärkende kombinationstherapie-komplexe
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
ATE461217T1 (de) Glp-1-verbindungen
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
BR0308923A (pt) OligÈmeros de nucleobase de iap anti-sentido e empregos destes
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
BRPI0411617A (pt) derivados de pirimidina como ligantes de receptores de canabinóides
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
CY1108395T1 (el) Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων
PL1651774T3 (pl) Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
TW200633995A (en) Andrographolide derivatives to treat viral infections
DE602005017626D1 (de) Antivirale verwendung von borinsäurekomplexen
DK1186672T3 (da) Polymorfismer i det humane gen for organiskaniontransporter C (OATP-C)
DE60309344D1 (de) Derivate von ä6, 7-dihydro -5h-imidazoä1,2 - aüimidazol -3 -sulfonylaminoü-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DK1553950T3 (da) Terapeutisk behandling
BRPI0409405A (pt) compostos 7-aza-quinazolina substituìdos
ATE373658T1 (de) Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины